Antisoma's AS1404 completes enrollment in phase 2 studies, prepares for phase 3

By Elaine Rigoli

Tampa, Fla., Aug. 15 - Antisoma plc said all of its phase 2 trials of AS1404 are now fully recruited and the company is now preparing for a phase 3 trial in lung cancer.

While preparing for the phase 3 trial, the company said it also completed enrollment in two more phase 2 studies:

• A controlled trial in hormone-refractory prostate cancer. A total of 74 men have been randomly assigned to receive either AS1404 plus docetaxel or docetaxel alone. This trial is being conducted at hospitals in the United States and Australia. It has been running alongside separate trials in lung and ovarian cancers.

• An extension of the phase 2 trial in non-small cell lung cancer. A further 24 patients have received 1,800 mg/m2 AS1404 in combination with carboplatin and paclitaxel in an open-label extension to the phase 2 lung cancer trial. Patients have been enrolled in Germany, Australia and New Zealand. This study is designed to further define the safety window for the drug.

Over the past two months, the company said there has been considerable interest from potential licensing partners for AS1404.

"There are few phase 3 oncology products available for licensing with strong data from controlled phase 2 studies, so it's not surprising that we've seen a high level of interest in AS1404. We are confident that we can secure a deal which reflects the advanced stage and blockbuster potential of this drug," chief executive officer Glyn Edwards said in the release.

Based in London, Antisoma is a biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.